CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 56 enrolled
Drug / intervention
BIA 9-1067drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02305329
NCT02305329Phase 1Completed
CompareCT.gov

Dosage Form Proportionality of Opicapone To-Be-Marketed Formulation in Healthy Subjects

Bial - Portela C S.A.·interventional·Posted Dec 2, 2014·Updated Aug 21, 2015

In Brief

A Phase 1 clinical trial evaluating BIA 9-1067 for Epilepsy. Completed, enrolled 56 participants.

Detailed Summary

Single-centre, open-label, randomized, two-sequence, two-way crossover study. The study consisted of two consecutive single-dose treatment periods separated by a washout period of 10 to 14 days or more.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 2, 2014
Enrollment StartFeb 1, 2014
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 11.6 years ago

Interventions

BIA 9-1067drug